Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Evofem Biosciences Q3 2026 Results: Turns Profitable, Net Income $1M

Evofem Biosciences reported a significant decline in total assets from $20.3 million at year-end 2025 to $7.3 million as of September 30, 2026, driven largely by a decrease in trade accounts receivable and intangible assets. The company faces substantial liquidity challenges with $84.8 million in current liabilities and has received notices of default from Future Pak, LLC regarding its debt obligations.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue4.65.0
Profit before tax1.0-1.6
Net income1.0-1.6
EPS (diluted, $ a share)$-0.00$-0.01

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year-6.5%
Operating margin16.0%
Source

10-Q filed with the SEC, OTC: EVFM. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Evofem Biosciences, Inc.: key numbers

Share price
$0.0060Close, Nov 13
Market cap
$795K
Shares outstanding
132.53MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Evofem Biosciences, Inc.

All →
5:00 PM ET 8-K
Financial Results

Evofem Biosciences Financial Results

Evofem Biosciences reported Q3 2026 financial results, achieving $0.7 million in operating income despite a slight decline in net sales to $4.6 million. The company highlighted the shipment of its 500,000th box of PHEXX and the addition of a fifth study site for an NIH-funded Phase 4 trial of SOLOSEC.

Term
Q3 2026

“While third quarter net sales reflect the cumulative impact of operating without dedicated growth capital for brand promotion and physician outreach since late 2022, we are proud of the discipline, efficiency and tenacity demonstrated across the organization. Through rigorous expense management, we generated $0.7 million of operating income during the quarter while continuing to support patients and healthcare providers who rely on our innovative sexual health products.”

Saundra Pelletier, CEO of Evofem
4:06 PM ET 8-K
Loan & Debt

Evofem Biosciences Debt Financing Update with Adjuvant Global Health Technology Fund, L.P.

Evofem Biosciences entered into a fifth amendment to its Securities Purchase Agreement with Adjuvant Global Health Technology Fund. The amendment extends the maturity date of outstanding convertible promissory notes to December 1, 2026, and removes certain affirmative covenants.

Counterparty
Adjuvant Global Health Technology Fund, L.P.
Term
through Dec 2026
4:06 PM ET 8-K
Capacity Expansion

Evofem Biosciences Capacity Expansion

Evofem Biosciences entered into a manufacturing agreement with Zhaoke Ophthalmology Pharmaceutical Limited to establish a second production source for its contraceptive gel, PHEXX. The expansion is designed to enhance supply chain flexibility and is expected to reduce unit costs by 40% or more once regulatory approval for the new facility is obtained.

Counterparty
Zhaoke Ophthalmology Pharmaceutical Limited

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.